Sai Life Sciences Ltd

Sai Life Sciences Ltd

₹ 723 -2.37%
22 May 3:25 p.m.
About

Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]

Key Points

Business Overview:[1]
a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe.
b) It offers integrated services across the pharmaceutical lifecycle from discovery services to development and manufacturing of new chemical entities to global innovator pharmaceutical and biotechnology companies.
c) In FY24, company has completed
200+ discovery programmes and 40+ programmes have advanced to clinical
phases.
d) SLS has a fully integrated in-house
synthetic and medicinal chemistry, drug metabolism, biology, pharmacokinetics
and toxicology.
e) In terms of therapy, they have worked in oncology and other key therapy areas include central nervous system, inflammation and anti
virals.
f) SLS provides its services to 17 out of the top 20 global pharmaceutical companies and several biotechnology companies.

  • Market Cap 15,065 Cr.
  • Current Price 723
  • High / Low 809 / 635
  • Stock P/E 86.8
  • Book Value 104
  • Dividend Yield 0.00 %
  • ROCE 13.9 %
  • ROE 10.9 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company's working capital requirements have reduced from 146 days to 109 days

Cons

  • Stock is trading at 7.05 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 8.50% over last 3 years.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2023 Mar 2024 Sep 2024 Dec 2024 Mar 2025
373 428 382 429 567
279 301 281 317 413
Operating Profit 94 127 101 111 154
OPM % 25% 30% 26% 26% 27%
11 4 10 9 10
Interest 22 19 19 22 9
Depreciation 28 28 33 31 34
Profit before tax 54 83 58 68 120
Tax % 26% 26% 25% 25% 25%
40 62 44 51 90
EPS in Rs 2.45 4.32
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
695 725 751 841 1,157 1,419 1,642
520 556 587 716 990 1,131 1,252
Operating Profit 175 170 164 125 167 288 390
OPM % 25% 23% 22% 15% 14% 20% 24%
6 18 27 28 27 29 37
Interest 24 21 32 51 74 81 70
Depreciation 44 52 72 80 88 107 126
Profit before tax 112 114 88 22 33 129 232
Tax % 35% 30% 25% 30% 26% 26% 25%
73 80 65 16 24 95 173
EPS in Rs 8.32
Dividend Payout % 0% 0% 0% 444% 279% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 18%
3 Years: 25%
TTM: 16%
Compounded Profit Growth
10 Years: %
5 Years: 17%
3 Years: 241%
TTM: 82%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: 7%
3 Years: 9%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 16 16 18 18 18 18 21
Reserves 700 778 850 873 895 993 2,147
250 304 637 752 870 868 287
246 291 312 464 349 361 682
Total Liabilities 1,212 1,389 1,816 2,106 2,131 2,240 3,137
373 617 659 701 923 1,074 1,378
CWIP 116 79 236 345 151 107 124
Investments 0 22 63 64 80 80 114
722 671 858 996 977 979 1,521
Total Assets 1,212 1,389 1,816 2,106 2,131 2,240 3,137

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
127 109 -26 88 221 251 330
-158 -259 -279 -95 -111 -190 -565
268 -1 304 81 -190 -85 314
Net Cash Flow 237 -152 -2 75 -80 -24 80

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 123 136 98 103 87 67 78
Inventory Days 86 77 124 185 123 73 96
Days Payable 208 247 244 284 176 161 270
Cash Conversion Cycle 0 -34 -21 4 35 -22 -96
Working Capital Days 133 144 250 246 190 140 109
ROCE % 13% 9% 4% 6% 11% 14%

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2024Mar 2025
35.23% 35.16%
11.72% 12.36%
11.95% 13.26%
41.08% 39.21%
No. of Shareholders 1,81,1221,40,677

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents